Page 61 - Bioterrorism

60

According to the WHO website: “A vaccine for the Influenza A(H1N1) virus will be produced
using licensed influenza vaccine processes in which the vaccine viruses are grown either in eggs
or cells. Candidate vaccine strains have been identified and prepared by the WHO Collaborating
Center in Atlanta (The Centers for Disease Control and Prevention (CDC) in the United States of
1
America) . These strains have now been received by the other WHO Collaborating Centers which
have also started preparation of vaccine candidate viruses. Once developed, these strains will be
distributed to all interested manufacturers on request. Availability is anticipated by mid-May.”

How can VICL have completed development of a prototype H1 vaccine, produced an initial
supply of research-grade material, and initiated immunogenicity testing in animals even before the
candidate vaccine was grown and released to companies unless VICL itself was involved in
making the virus in the first place.

How can VICL have won a contract with the Navy for clinical testing of a vaccine when the
candidate virus has not even been released by WHO?

“The first doses of Influenza A(H1N1) vaccine could be available in five to six months from
identification of the pandemic strain. The regulatory approval will be conducted in parallel with
the manufacturing process. Regulatory authorities have put into place expedited processes that do
not compromise on the quality and safety of the vaccine. Delays in production could result from
poor growth of the virus strain used to make the vaccine,” WHO says on its website.

VICL is working to a very different time plan.

„Assuming a successful outcome of this testing and a commitment for program-specific external
funding, the company is ready to advance directly to large-scale cGMP manufacturing of vaccine
for human clinical trials to be conducted by the U.S. Navy.

The company previously announced that it has entered into a Cooperative Research and
Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC), a
biomedical research organization within the U.S. Navy, to advance into clinical testing as quickly
as possible a Vaxfectin(r)-formulated H1 DNA vaccine. Vical and the NMRC are actively
pursuing funding to support the program.“

Criminal charges have also been brought against WHO, Baxter and the Swiss National Influenza
Laboratory in Geneva for their role in an alleged bioterrorist attack in Switzerland on April 27th.
(see Attachment (B) for charges in German)

A container with vials of swine flu virus exploded on a Swiss Intercity train at peak time,
exposing 61 people to a potentially lethal virus.

(http://uk.reuters.com/article/worldNews/idUKTRE53R1PO20090428)

The container appears to have come from a WHO and Baxter affiliated laboratory in Mexico City.
It was destined for the National Influenza Laboratory of Switzerland in Geneva, but was
apparently sent by plane to Zurich where it was picked up by a technician.

The container was faultily packaged. The dry ice meant to cool the vials was packed into the
wrong part of the container and resulted in an explosion as the dry ice melted in the train
compartment.

The allegation is that these groups were acting in unison to rlease a virulent strain of the virus
among the Swiss population and cause panic in an attempt to justify triggering a pandemic level 6